DK167253B1 - 2-alkyl-3-benzoylfuranderivater, laegemidler indeholdende disse samt anvendelse af derivaterne til fremstilling af laegemidler - Google Patents
2-alkyl-3-benzoylfuranderivater, laegemidler indeholdende disse samt anvendelse af derivaterne til fremstilling af laegemidler Download PDFInfo
- Publication number
- DK167253B1 DK167253B1 DK183789A DK183789A DK167253B1 DK 167253 B1 DK167253 B1 DK 167253B1 DK 183789 A DK183789 A DK 183789A DK 183789 A DK183789 A DK 183789A DK 167253 B1 DK167253 B1 DK 167253B1
- Authority
- DK
- Denmark
- Prior art keywords
- formula
- derivatives
- alkyl
- compounds
- preparation
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title description 4
- 229940126601 medicinal product Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 206010003119 arrhythmia Diseases 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 6
- 239000011149 active material Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 230000003288 anthiarrhythmic effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229960004194 lidocaine Drugs 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000003416 antiarrhythmic agent Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 150000003931 anilides Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 229940051881 anilide analgesics and antipyretics Drugs 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 3
- 229960000244 procainamide Drugs 0.000 description 3
- 229960001404 quinidine Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000003663 ventricular fibrillation Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OXICMBCQSJVXDK-UHFFFAOYSA-N 2-butyl-1-benzofuran-3-carbonyl chloride Chemical compound C1=CC=C2C(C(Cl)=O)=C(CCCC)OC2=C1 OXICMBCQSJVXDK-UHFFFAOYSA-N 0.000 description 2
- HZRZFZYFVRQMPA-UHFFFAOYSA-N 2-propyl-1-benzofuran-3-carbonyl chloride Chemical compound C1=CC=C2C(C(Cl)=O)=C(CCC)OC2=C1 HZRZFZYFVRQMPA-UHFFFAOYSA-N 0.000 description 2
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- -1 N-diethylaminoacetylamino Chemical group 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical group [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- WKBALTUBRZPIPZ-UHFFFAOYSA-N 2,6-di(propan-2-yl)aniline Chemical compound CC(C)C1=CC=CC(C(C)C)=C1N WKBALTUBRZPIPZ-UHFFFAOYSA-N 0.000 description 1
- FOYHNROGBXVLLX-UHFFFAOYSA-N 2,6-diethylaniline Chemical compound CCC1=CC=CC(CC)=C1N FOYHNROGBXVLLX-UHFFFAOYSA-N 0.000 description 1
- RZSUJIUTUGMZPG-UHFFFAOYSA-N 2,6-ditert-butylaniline Chemical compound CC(C)(C)C1=CC=CC(C(C)(C)C)=C1N RZSUJIUTUGMZPG-UHFFFAOYSA-N 0.000 description 1
- OVJKFJDEVKABNF-UHFFFAOYSA-N 2-butyl-1-benzofuran Chemical class C1=CC=C2OC(CCCC)=CC2=C1 OVJKFJDEVKABNF-UHFFFAOYSA-N 0.000 description 1
- VONWPEXRCLHKRJ-UHFFFAOYSA-N 2-chloro-n-phenylacetamide Chemical compound ClCC(=O)NC1=CC=CC=C1 VONWPEXRCLHKRJ-UHFFFAOYSA-N 0.000 description 1
- GNBSANLSOKLGAN-UHFFFAOYSA-N 2-ethyl-1-benzofuran-3-carbonyl chloride Chemical compound C1=CC=C2C(C(Cl)=O)=C(CC)OC2=C1 GNBSANLSOKLGAN-UHFFFAOYSA-N 0.000 description 1
- HETKNTVNNORVAA-UHFFFAOYSA-N 3h-1-benzofuran-2-ylidenemethanone Chemical class C1=CC=C2OC(=C=O)CC2=C1 HETKNTVNNORVAA-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- ZSSUKQHPALINBY-UHFFFAOYSA-N Secamine Natural products CCC1=CCCN(CCc2c3C(CCC(C(=O)OC)(c4[nH]c5ccccc5c4CCN6CCC=C(CC)C6)n3c7ccccc27)C(=O)OC)C1 ZSSUKQHPALINBY-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical group [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010013395 disorientation Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000011968 lewis acid catalyst Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- CBPYOHALYYGNOE-UHFFFAOYSA-M potassium;3,5-dinitrobenzoate Chemical compound [K+].[O-]C(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 CBPYOHALYYGNOE-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/182,402 US4831054A (en) | 1988-04-18 | 1988-04-18 | 2-Alkyl-3-benzoylbenzofurans useful for treating cardiac arrhythmia |
| US18240288 | 1988-04-18 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK183789D0 DK183789D0 (da) | 1989-04-17 |
| DK183789A DK183789A (da) | 1989-10-19 |
| DK167253B1 true DK167253B1 (da) | 1993-09-27 |
Family
ID=22668313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK183789A DK167253B1 (da) | 1988-04-18 | 1989-04-17 | 2-alkyl-3-benzoylfuranderivater, laegemidler indeholdende disse samt anvendelse af derivaterne til fremstilling af laegemidler |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4831054A (ja) |
| EP (1) | EP0338746B1 (ja) |
| JP (1) | JP2701933B2 (ja) |
| AT (1) | ATE110721T1 (ja) |
| AU (1) | AU616134B2 (ja) |
| CA (1) | CA1296734C (ja) |
| DE (1) | DE68917772T2 (ja) |
| DK (1) | DK167253B1 (ja) |
| ES (1) | ES2063815T3 (ja) |
| IE (1) | IE65529B1 (ja) |
| IL (1) | IL89908A0 (ja) |
| ZA (1) | ZA892695B (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2665444B1 (fr) * | 1990-08-06 | 1992-11-27 | Sanofi Sa | Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant. |
| US5234949A (en) * | 1992-04-01 | 1993-08-10 | Academic Pharmaceuticals, Inc. | Parenteral solutions containing amiodarone in acetate buffer solution |
| JPH06124078A (ja) * | 1992-10-13 | 1994-05-06 | Max Co Ltd | 欧文文書処理に於けるカーニング処理方法 |
| DE19547263C2 (de) * | 1995-12-07 | 1999-04-29 | Cardiotec Inc | Amidinohydrazone vom Benzo[b]furan abgeleiteter Ketone, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| FR2764800B1 (fr) | 1997-06-23 | 1999-09-10 | Sanofi Sa | Composition pharmaceutique solide contenant des derives de benzofuranne |
| US6030998A (en) * | 1997-06-27 | 2000-02-29 | Academic Pharmaceuticals, Lp | Methods for treating arrhythmia using acetate buffer solutions of amiodarone |
| FR2813306B1 (fr) * | 2000-08-23 | 2005-10-21 | Sanofi Synthelabo | Aminoalkybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation et les compositions les contenant |
| FR2813307B1 (fr) * | 2000-08-23 | 2002-11-08 | Sanofi Synthelabo | Aminoalkenylbenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation et les compositions les contenant |
| FR2813308B1 (fr) | 2000-08-23 | 2005-07-01 | Sanofi Synthelabo | Aminoalkoxybenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation ainsi que les compositions les contenant |
| FR2864536B1 (fr) * | 2003-12-24 | 2006-03-17 | Clariant France Sa | Procede de preparation de n-alkyl-2 (hydroxy-4-benzoyl)-3 benzofurannes et intermediaires pour sa mise en oeuvre |
| NZ588623A (en) | 2008-04-17 | 2012-11-30 | Sanofi Aventis | Use of a medicament containing dronedarone with food for preventing cardiovascular hospitalization |
| US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
| FR2967067A1 (fr) | 2010-11-10 | 2012-05-11 | Sanofi Aventis | Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3012042A (en) * | 1956-12-21 | 1961-12-05 | Belge Produits Chimiques Sa | Benzofurans |
| US3331845A (en) * | 1963-04-04 | 1967-07-18 | American Cyanamid Co | 1-substituted-4-substituted amino alkylene piperazines |
| GB1521932A (en) * | 1976-03-08 | 1978-08-16 | Labaz | Sulphonamide derivatives and process for preparing the same |
| FR2549475B1 (fr) * | 1983-07-18 | 1986-02-07 | Labaz Sanofi Nv | Nouveaux derives de benzofuranne, leur preparation et leur utilisation therapeutique |
-
1988
- 1988-04-18 US US07/182,402 patent/US4831054A/en not_active Expired - Lifetime
-
1989
- 1989-04-11 IL IL89908A patent/IL89908A0/xx not_active IP Right Cessation
- 1989-04-13 ZA ZA892695A patent/ZA892695B/xx unknown
- 1989-04-14 IE IE119989A patent/IE65529B1/en not_active IP Right Cessation
- 1989-04-17 EP EP89303772A patent/EP0338746B1/en not_active Expired - Lifetime
- 1989-04-17 ES ES89303772T patent/ES2063815T3/es not_active Expired - Lifetime
- 1989-04-17 AT AT89303772T patent/ATE110721T1/de not_active IP Right Cessation
- 1989-04-17 DK DK183789A patent/DK167253B1/da not_active IP Right Cessation
- 1989-04-17 DE DE68917772T patent/DE68917772T2/de not_active Expired - Fee Related
- 1989-04-17 AU AU33094/89A patent/AU616134B2/en not_active Ceased
- 1989-04-18 JP JP1098644A patent/JP2701933B2/ja not_active Expired - Fee Related
- 1989-04-18 CA CA000596999A patent/CA1296734C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2701933B2 (ja) | 1998-01-21 |
| IL89908A0 (en) | 1989-12-15 |
| JPH0242073A (ja) | 1990-02-13 |
| ATE110721T1 (de) | 1994-09-15 |
| US4831054A (en) | 1989-05-16 |
| ES2063815T3 (es) | 1995-01-16 |
| IE891199L (en) | 1989-10-18 |
| AU3309489A (en) | 1989-10-19 |
| DK183789D0 (da) | 1989-04-17 |
| DE68917772D1 (de) | 1994-10-06 |
| ZA892695B (en) | 1989-12-27 |
| EP0338746A1 (en) | 1989-10-25 |
| IE65529B1 (en) | 1995-11-01 |
| DE68917772T2 (de) | 1995-03-02 |
| CA1296734C (en) | 1992-03-03 |
| DK183789A (da) | 1989-10-19 |
| EP0338746B1 (en) | 1994-08-31 |
| AU616134B2 (en) | 1991-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK167253B1 (da) | 2-alkyl-3-benzoylfuranderivater, laegemidler indeholdende disse samt anvendelse af derivaterne til fremstilling af laegemidler | |
| EP0202589B1 (en) | Pharmaceutical compositions containing ascorbic acid derivatives | |
| DE60133323T2 (de) | Cardioprotektive Phosphonate | |
| EP0350012A2 (en) | Antiviral composition | |
| KR910005708B1 (ko) | 1,5-벤조티아제핀 유도체의 제조방법 | |
| RU2213560C2 (ru) | Фармацевтическая композиция, содержащая сочетание правовращающего и левовращающего изомеров соталола | |
| KR880000786B1 (ko) | 피페라진 유도체의 제조방법 | |
| US3726980A (en) | Pharmaceutical preparations containing anilides of quinuclidine-2-and quinuc lidine-3-carboxylic acid and methods for using them | |
| JP3885900B2 (ja) | ベンゾピラン誘導体及びそれを有効成分とする心臓疾患治療剤 | |
| US4000192A (en) | Pharmacologically active compounds | |
| JP4684514B2 (ja) | 心性不整脈の治療のための新規鏡像異性体化合物およびその使用法 | |
| US6479676B1 (en) | OxiranEcarboxylic acids for the treatment of diabetes | |
| US3527871A (en) | Method of treating arrhythmia | |
| US4053603A (en) | Benzylisoquinoline derivatives, and use as anti-arrhythmic drugs | |
| US3868463A (en) | Method of treating arrhythmia | |
| US4237068A (en) | Primary aminoacylanilides | |
| PL113904B1 (en) | Process for preparing novel derivatives of indolysine | |
| US4146628A (en) | Antiarrhythmic quinuclidine carboxylic acid xylidide and method of producing the same and similar compounds | |
| US4831049A (en) | Pyrrolizidine compounds, and their use as antiarrhythmic agents | |
| US3907999A (en) | Substituted dibenzocyclooctene compositions | |
| US4975458A (en) | 2-alkyl-3-benzoylbenzofurans useful for treating cardiac arrhythmia | |
| DE2014201C3 (de) | Hydrochlorid des 10-(beta-morpholinopropionyl)-phenothiazin-2-carbamin-saeureaethylesters, verfahren zu dessen herstellung und pharmazeutisches mittel | |
| JPH0374233B2 (ja) | ||
| US3988454A (en) | Phenylalkylaralkylamines for pharmaceutical use | |
| US3433789A (en) | S-benzoyloxymethyl-thiamines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B1 | Patent granted (law 1993) | ||
| PBP | Patent lapsed |
Country of ref document: DK |